+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 19 Actively Recruiting clinical trials

O

Actively Recruiting

Diffuse large B-cell lymphoma DLBCL is the most common and aggressive subtype of non-Hodgkin lymphoma NHL, affecting many patients with rapid tumor growth and symptoms depending on tumor location. This observational study aims to understand the clinical characteristics, treatment patterns, and access to new therapies for patients with DLBCL in the Middle East and Africa region, including both newly diagnosed and relapsed or refractory cases. Participants are grouped into two cohorts those who are newly diagnosed and eligible for treatment, and those who have relapsed or are refractory after at least one prior therapy. The study does not involve experimental treatments but collects information on how patients are treated in real-world settings and explores access to innovative therapies. During the study, patient demographics, disease characteristics, risk profiles, and treatment patterns are documented over 22 months. Researchers will gather data through reviews of medical records and clinical information without administering treatments. The primary goal is to describe first-line and subsequent treatment approaches and to understand patient access to novel therapies for DLBCL.

All AgesAll Genders
21 locations
R

Actively Recruiting

Researchers are evaluating luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle East. This observational study aims to understand how luspatercept affects the need for blood transfusions and hemoglobin levels in real-world clinical settings. The study is sponsored by Bristol-Myers Squibb and focuses on adults who have started luspatercept treatment within the past year. Participants receive luspatercept as prescribed according to the product label, with no experimental intervention assigned by the study. The study observes ongoing treatment and collects data retrospectively and prospectively, following participants for up to 144 weeks. Key measurements include changes in transfusion burden, pre-transfusion hemoglobin, and iron levels, among other clinical and healthcare utilization outcomes. During the study, participants provide signed consent and allow researchers to collect medical data relevant to their treatment with luspatercept. Researchers monitor transfusion visits, hemoglobin levels, treatment duration, dose adjustments, and other health indicators. The study includes comprehensive data collection on participants disease characteristics, comorbidities, and treatment history, aiming to provide a detailed understanding of luspatercepts use over nearly three years.

Age: 18Years +All Genders
13 locations
I

Actively Recruiting

Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN is a very rare blood cancer with no agreed-upon best treatment. Researchers are working internationally to gather detailed information on how BPDCN presents, how it is diagnosed, the treatments patients receive, and their outcomes. The study aims to build a large database to better understand the disease and to develop treatment recommendations based on collected data. This study is an international registry collecting information from multiple centers about patients diagnosed with BPDCN. It includes both retrospective and prospective data from patients worldwide. The data collected covers patient details, disease characteristics, treatment information, outcomes, causes of death, and the conclusion of data collection. Consent will be obtained from prospective patients, and quality control is managed by the Immune Oncology Research Institute. Participants will provide information through questionnaires completed by their treatment centers. Researchers will analyze overall survival, complete remission rates, duration of first remission, and event-free survival over five years. This observational study does not involve treatment but gathers and monitors detailed clinical data to improve understanding and guide future therapies for BPDCN.

All AgesAll Genders
22 locations
A

Actively Recruiting

Hepatocellular carcinoma HCC is a common and serious cancer worldwide, often linked to cirrhosis caused by hepatitis B or C viruses and steatotic liver disease. This research focuses on understanding the causes, patient and tumor characteristics, treatments, and outcomes of HCC in adults across various countries in the Middle East and North Africa region, where the disease burden is significant. Differences in healthcare resources and access in these countries affect diagnosis and treatment outcomes. The study collects and reviews existing medical records of adult patients diagnosed with HCC between 2015 and 2023 in the MENA region. It examines details such as patient demographics, tumor features, risk factors, and treatment methods used. This observational study uses secondary data collection without administering any new treatments or interventions. Participants will have their clinical information, laboratory tests, imaging results, and treatment histories analyzed from medical records. The research team will assess outcomes like overall survival and progression-free survival over an eight-year period. Data completeness and follow-up for at least six months are required for inclusion. The study aims to improve understanding of HCC management and outcomes in this region through detailed data review.

All AgesAll Genders
17 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a method to detect Type 1 Diabetes T1D early in children and adolescents who have a first-degree relative with T1D. The study aims to establish standardized screening, monitoring, and data collection for pre-symptomatic T1D in line with international guidelines. The trial is designed as a diagnostic study lasting approximately 13 months with two main visits. Participants will have blood samples collected to test for autoantibodies related to T1D. If any autoantibodies are found, additional tests including another autoantibody test, HbA1C test, and either an Oral Glucose Tolerance Test OGTT or Continuous Glucose Monitoring CGM will be performed. These procedures are conducted during two visits the initial screening visit and a confirmatory visit three months later. During the study, participants will undergo these tests to monitor for early signs of T1D development. Researchers will measure the proportion of at-risk relatives who meet diagnostic criteria for early stages of T1D at baseline and after three months. They will also track acceptance and refusal rates for screening and follow-up. Participants will be monitored over the 13-month period with no investigational drugs administered, focusing on diagnostic procedures and data collection.

Age: 18Months - 18YearsAll GendersPhase Not Applicable
7 locations
E

Actively Recruiting

This research aims to study the short- and long-term effects of adding a comprehensive fall prevention program to regular physiotherapy for elderly women who have undergone total knee replacement TKR due to osteoarthritis. It focuses on reducing the number of falls, improving balance, and enhancing functional ability. The study is a single-blinded, randomized controlled trial lasting 24 weeks, involving older adults treated at Al-Razi Orthopedic Hospital. Participants will be divided into two groups. The control group will receive conventional physiotherapy that includes exercises to improve blood circulation, strengthen muscles, increase knee range of motion, and gait training. The experimental group will receive the same physiotherapy plus a fall prevention program featuring Otago balance exercises, personalized advice on assistive devices based on balance scores, environmental hazard checks, and guidance on vision care and footwear. Both groups will follow a home exercise program. During the study, participants will be monitored for falls at baseline, 12 weeks, and one year. Assessments will include knee range of motion and patient satisfaction at 12 weeks and one year. Adherence to the exercise programs will also be tracked. The trial aims to evaluate how well the combined treatment improves outcomes compared to physiotherapy alone, with safety and functional recovery closely observed throughout the study period.

Age: 60Years +FEMALEPhase Not Applicable
1 location
I

Actively Recruiting

Researchers are conducting an international, multicenter, prospective observational study called EXTUBE to evaluate the frequency, risk factors, and outcomes of complications related to extubation after general anesthesia or critical illness. Extubation is a common but potentially risky procedure performed in the operating room, other anesthesia locations, or intensive care units. The study aims to better understand severe and mild extubation complications, adherence to clinical guidelines, and patient outcomes up to hospital discharge. The study does not involve treatments but observes extubations performed in routine clinical care settings. It includes adult patients undergoing extubation of an endotracheal tube during a specified enrollment period. Researchers will collect detailed data on extubation events, clinical practices, and complications occurring within 60 minutes and up to 7 days after extubation. Participants will be monitored closely during and after extubation to record events such as severe hypoxemia, cardiac arrest, airway management needs, and other complications. Data collection includes outcomes up to hospital discharge and reintubation events within 48 hours. The study will also evaluate adherence to extubation guidelines and report reasons for any exclusions. Participation duration covers the extubation event and hospital stay until discharge.

Age: 18Years +All Genders
35 locations
P

Actively Recruiting

Healthy Volunteer

Lung cancer is a major cause of cancer-related death in Kuwait, where most cases are detected at advanced stages and no national screening program currently exists. This prospective pilot feasibility study aims to assess the acceptance and challenges of low-dose computed tomography LDCT lung cancer screening among high-risk adults aged 50 to 80 years. The goal is to develop a foundation for a future national screening program. Participants are recruited at Ministry of Health polyclinics and hospital chest clinics, with screening conducted at the Chest Diseases Hospital. Each participant undergoes eligibility and baseline assessments before being offered three LDCT screening rounds one at enrollment and two annual follow-ups. The Lung-RADS system guides management, including annual screening for low-risk categories, short-interval CT scans for moderate risk, and immediate referral for high-risk findings. Radiologists interpret the scans without artificial intelligence during the study AI analysis will be performed later on archived scans. Participants will complete baseline and annual LDCT scans with follow-up based on Lung-RADS results. Researchers will measure consent rates, scan completion, screening barriers, lung cancer detection rates, and participant experiences over approximately 24 months. Additional assessments include radiation exposure, incidental findings, adherence to follow-up, and AI software performance in a separate reader study. This comprehensive monitoring aims to inform Kuwaits lung cancer screening guidelines and improve early detection.

Age: 50Years - 80YearsAll GendersPhase Not Applicable
1 location
C

Actively Recruiting

Healthy Volunteer

Metabolic dysfunction-associated steatotic liver disease MASLD, previously called non-alcoholic fatty liver disease NAFLD, is a common chronic liver condition linked to obesity, diabetes, and dyslipidemia. This condition ranges from simple fat buildup in the liver to more severe forms like metabolic dysfunction-associated steatohepatitis MASH, which can cause liver injury, advanced fibrosis, cirrhosis, or liver cancer. Patients with MASH also face risks of cardiovascular disease and death. Currently, there is no universally approved medication for MASH, and weight loss remains the main treatment approach. This study is a randomized controlled trial comparing two treatments for adults with obesity and biopsy-confirmed MASH and liver fibrosis. Participants will be randomly assigned to receive either metabolic surgery including Roux-en-Y Gastric Bypass or Sleeve Gastrectomy or medical treatment using incretin-based therapies such as liraglutide, semaglutide, or tirzepatide. The study will follow participants for two years, after which a repeat liver biopsy will assess changes in liver fibrosis and MASH. Participants will undergo a baseline liver biopsy if none is available, followed by treatment with either surgery or medication. Throughout the two-year study, they will be monitored regularly, with assessments including liver biopsies to measure fibrosis improvement or progression, resolution of MASH, weight changes, and quality of life. Safety and treatment adherence will also be tracked to understand the impact of these interventions on liver health and overall well-being.

Age: 18Years - 75YearsAll GendersPhase 4
22 locations
I

Actively Recruiting

Researchers are observing patients with Gaucher disease in the International Collaborative Gaucher Group ICGG Gaucher Registry to understand the diseases variability, progression, and natural history. The study aims to help guide treatment decisions and improve patient care by providing data on patient outcomes and the long-term effectiveness of treatments like imiglucerase and eliglustat. There is also a Gaucher Pregnancy Sub-registry focusing on pregnancy outcomes and infant growth in women with Gaucher disease. Participants in the Registry do not receive experimental treatments but continue with their usual clinical assessments and care as determined by their physicians. The Pregnancy Sub-registry collects data from pregnant women with Gaucher disease, including medical and obstetric history, pregnancy, birth details, and infant growth up to 36 months postpartum. Both registries do not involve any experimental interventions and support standard care practices. During the study, participants undergo routine clinical assessments and provide medical data as part of their ongoing care. Data collected includes patient outcomes, monitoring recommendations, and pregnancy-related information when applicable. The studys primary outcomes include generating monitoring guidelines for Gaucher disease and tracking pregnancy and infant growth outcomes. The registry is ongoing and international, with data collected over several decades to enhance understanding and optimize care for Gaucher disease.

All AgesAll Genders
317 locations

1-10 of 19

1